Adverse events (all) · adults with asthma not well controlled on ICS
Long‐acting muscarinic antagonists (LAMA) add‐on showed no clear difference in adverse events (all) compared with long‐acting beta2‐agonists (LABA) add‐on (moderate certainty).
1 finding from 1 review
Overall serious adverse events · people who smoke
1 finding from 1 review
All adverse events · Adults with acute asthma
It is very uncertain whether adults: higher dose/longer course changes all adverse events compared with lower dose/shorter course (very low certainty).
1 finding from 1 review
All adverse events · children with acute asthma
Children: higher dose/longer course showed no clear difference in all adverse events compared with lower dose/shorter course (moderate certainty).
1 finding from 1 review
Adverse events Assessed clinically · patients with functional dyspepsia
Curcuma longa showed no clear difference in adverse events Assessed clinically compared with placebo (moderate certainty).
1 finding from 1 review
Overall local/injection site adverse events · 9‐ to 14‐year‐old females and males
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events: all cause – long term · people with schizophrenia or other serious mental illness
It is very uncertain whether peer support plus standard care changes adverse events: all cause – long term compared with standard care (very low certainty).
1 finding from 1 review
Overall adverse events (pooled short and long term) · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes overall adverse events (pooled short and long term) compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review
Falls · Nursing home residents (mean age 78.3 to 86.0 years; more than 66% women; 62.1% to 87.3% with dental prostheses)
It is very uncertain whether summary of findings: Any alternative model of care changes adverse events/falls: proportion of residents with a fall at longest compared with usual care (very low certainty).
1 finding from 1 review
Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) · Healthcare workers (HCWs) treating patients with suspected or confirmed COVID-19 infection
The review found no eligible studies for this question.
1 finding from 1 review
Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) · Patients with suspected or confirmed COVID-19 infection
The review found no eligible studies for this question.
1 finding from 1 review
Other adverse events (allergy, irritation/burning of nasal, oral or oropharyngeal mucosa, long-term staining of mucous membranes or teeth, accidental ingestion) · Patients without suspected or confirmed COVID-19 infection undergoing aerosol-generating procedures (AGPs), and the healthcare workers…
The review found no eligible studies for this question.
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Phentermine/topiramate may leads to higher all adverse events compared with placebo (low certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
Naltrexone/bupropion probably leads to higher all adverse events compared with placebo (moderate certainty).
1 finding from 1 review
All adverse events · Men and non‐pregnant women ≥ 18 years old with essential hypertension
It is very uncertain whether orlistat changes all adverse events compared with placebo (very low certainty).
1 finding from 1 review
All adverse events · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment showed no clear difference in all adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events (all) · adults with asthma well controlled on LABA and ICS
Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).
1 finding from 1 review
All‐cause serious adverse events 24 weeks · adults with asthma not well controlled on ICS
LAMA add‐on showed no clear difference in all‐cause serious adverse events 24 weeks compared with ICS alone (low certainty).
1 finding from 1 review